NCI's MATCH Trial Evaluates Genetic Testing for Targeted Therapy in Advanced Cancers
The MATCH trial investigates the efficacy of treatment guided by genetic testing in patients with advanced refractory solid tumors, lymphomas, or multiple myeloma.
Company
Pharmaceutical intelligence for oncology therapeutics companies with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.